An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer

Abstract

The treatment of colon cancer is a major healthcare issue that requires exploration of several treatment approaches. With an emphasis on overall survival, progression-free survival, and adverse events, this meta-analysis attempts to evaluate the efficacy and safety of TAS-102 and FOLFOX as a combination medication. The findings show that TAS-102 and FOLFOX both improve overall and progression-free survival, but that TAS-102 is more effective in the latter regard. There are significant variations in safety profiles between FOLFOX and TAS-102. TAS-102 shows better results, such as smaller confidence intervals and less severe side effects. The analyzed research indicates minimal publication bias. It is imperative to proceed with caution when generalizing these results to other demographic analysis.